Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles

Area of Science:

• Oncology
• Muscle Physiology
• Pharmacology

Background:

• Sarcopenia, common in cancer patients, worsens adverse reactions and survival post-antitumor therapy.
• Antitumor drugs interact with cancer-induced muscle wasting, complicating treatment outcomes.
• Dynamic skeletal muscle changes during therapy, not just baseline measurements, are increasingly recognized.

Purpose of the Study:

• To review research on the relationship between antitumor drugs and dynamic skeletal muscle changes during cancer treatment.
• To synthesize current understanding of how cancer therapies affect muscle mass and composition.

Main Methods:

• Systematic retrieval of English-language original research articles from PubMed.
• Focus on studies measuring skeletal muscle index repeatedly using computed tomography (CT).
• Inclusion of cancer patients receiving antitumor drugs without confounding interventions like exercise or nutrition.

Main Results:

• Most antineoplastic drugs induce skeletal muscle loss during treatment.
• Loss of the L3 skeletal muscle index is consistently linked to poorer clinical outcomes.
• Dynamic changes in muscle mass during therapy are a critical factor.

Conclusions:

• Antitumor drug administration frequently leads to skeletal muscle depletion.
• Monitoring dynamic skeletal muscle changes is crucial for predicting patient prognosis.
• Skeletal muscle loss during treatment is a significant indicator of adverse clinical outcomes.